FDA reminded investors about risks tied to advisory panels, citing two companies facing briefing-document scrutiny and sharp stock reactions ahead of FDA meetings. The update highlighted how similar briefing packages can contribute to volatility and how regulators’ concerns often focus on clinical data interpretation and study design sufficiency. While the note did not conclude outcomes, it framed the agency’s emphasis on trial evidence quality and the risk that advisory panel dynamics can magnify market expectations around pivotal or approval-adjacent decisions. For companies, this can affect investor perception and timing for response to FDA feedback. The reminder also underscores how procedural steps—what the FDA includes in briefing documents and how it summarizes efficacy and safety concerns—can drive near-term repricing. For the biotech sector, the episode adds to a growing pattern: capital markets now price regulatory uncertainty not just on data, but also on how evidence is presented and debated before expert advisers.